• Quest Diagnostics outlined 2025 corporate responsibility progress, citing scale of about 244 million test requisitions processed across roughly 8,000 patient access points.
• Reported 1 million or more discounted or donated test requisitions, framed as part of broader access and community health initiatives.
• Highlighted consumer-initiated testing expansion to more than 150 tests on questhealth.com, pointing to a push toward prevention-focused services.
• Flagged pipeline momentum in oncology and neurology, including FDA Breakthrough Device Designation for Haystack MRD and a new blood-based Alzheimer’s test.
• Noted operational sustainability actions, including a 2.1 million-plus reduction in miles driven, 1.1 million kWh generated from waste-to-energy, ISO 14001:2015 certification at five labs.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Quest Diagnostics Incorporated published the original content used to generate this news brief on June 15, 2026, and is solely responsible for the information contained therein.